<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38934">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599532</url>
  </required_header>
  <id_info>
    <org_study_id>14-1455</org_study_id>
    <nct_id>NCT02599532</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The nephrotic syndrome (NS) is characterized by proteinuria and hypoalbuminemia, and
      patients with nephrotic syndrome are known to be hypercoaguable with increased incidence of
      venous thromboembolism necessitating anticoagulation. While classically warfarin has been
      used as an anticoagulant in NS, newer oral anticoagulants, such as apixaban, are
      increasingly used to treat venous thromboembolism (VTE) in the general population. It is
      unknown how hypoalbuminemia and proteinuria affect the pharmacokinetics and pharmacodynamics
      of apixaban. This study is to investigate the pharmacokinetics and pharmacodynamics of
      apixaban in nephrotic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a parallel arm, single-dose pilot study of the pharmacokinetics of apixaban in
      adults with nephrotic syndrome. Goal enrollment of twenty subjects with non-diabetic
      nephropathy and albumin ≤ 2.8 g/dl and ten healthy control subjects without nephrotic
      syndrome. Each subject will be administered a single dose of apixaban 10 mg. Plasma drug
      concentration level and plasma anti-Xa activity levels will be measured at 3, 6, and 24
      hours after drug administration in order to determine the maximum plasma concentration of
      apixaban, area under the curve, and half-life of apixaban in the setting of hypoalbuminemia
      and proteinuria due to nephrotic syndrome. Apixaban levels will be measured via
      liquid-chromatography spectrometry mass. Additionally, thrombin generation will be measured
      at 0, 3, 6, and 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>apixaban plasma levels</measure>
    <time_frame>12 months</time_frame>
    <description>maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve (AUC)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>half-life of apixaban</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>apixaban anti-Xa level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombin generation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Nephrotic syndrome</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 3 hours, 6 hours, and 24 hours after drug administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-nephrotic syndrome</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 3 hours, 6 hours, and 24 hours after drug administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <description>Study subjects will be given a single-dose of apixaban 10 mg.</description>
    <arm_group_label>Nephrotic syndrome</arm_group_label>
    <arm_group_label>Non-nephrotic syndrome</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-79 years old

          -  nephrotic syndrome subjects: hypoalbuminemia as defined by albumin &lt;2.8 mg/dl
             attributable to non-diabetic nephrotic syndrome

        Exclusion Criteria:

          -  Creatinine ≥ 1.5 AND weight ≤ 60kg

          -  on dialysis

          -  baseline prolonged prothrombin time(PT)/ international normalized ratio (INR),
             partial thromboplastin time (PTT)

          -  platelets less than 100,000

          -  history of gastrointestinal bleed

          -  history of intracranial bleed

          -  history of stroke

          -  use of the following medications within the past 14 days:

               -  inducers of cytochrome P450 3A4 (CYP3A4): rifampin, carbamazepine, phenytoin,
                  St. John's wort

               -  strong inhibitors of cytochrome P450 3A4 (CYP3A4): ketoconazole, ritonavir,
                  clarithromycin

               -  antiplatelet and/ or anticoagulant agents: heparin, aspirin, clopidogrel,
                  prasugrel, nonsteroidal anti-inflammatory medicaitons, warfarin

               -  selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine
                  reuptake inhibitor (SNRI)

          -  pregnancy/ breastfeeding

          -  liver disease

          -  lupus

          -  diabetic nephropathy

          -  congestive heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karlyn Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vimal Derebail, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karlyn Martin, MD</last_name>
    <phone>919-966-1996</phone>
    <email>karlyn.martin@unchealth.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vimal Derebail, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlyn Martin, MD</last_name>
      <phone>919-966-1996</phone>
      <email>karlyn.martin@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Vimal Derebail, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Burghardt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 3, 2016</lastchanged_date>
  <firstreceived_date>November 4, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Karlyn Martin, MD</investigator_full_name>
    <investigator_title>Fellow, Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>Apixaban</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
